Chemours CC Plunges 10.01% as Q3 Earnings Loom, Analysts Predict 40% EPS Decline

The share price fell to its lowest level since this month, with an intraday decline of 1.39% on Nov. 6.

The Chemours (CC) has fallen for a third consecutive session, dropping 10.01% over the period, as investors await its Q3 2025 earnings report set for Nov. 6 after market close. Analysts expect the company to report earnings per share of $0.24, a 40% year-over-year decline, with revenue flat at $1.5 billion. Recent downward revisions to both EPS and revenue estimates—nine and six, respectively, over the past three months—signal waning confidence in the company’s ability to navigate industry headwinds, including cost pressures and weak demand. A miss on earnings or revenue could trigger further selling, while a beat might offer temporary relief.

Technical indicators also highlight near-term volatility. The stock’s 14-day RSI dipped below 30 to 29.4, entering oversold territory, suggesting potential undervaluation. Traders may view this as a contrarian buying opportunity, though the move aligns with broader weakness in the chemical sector, which remains sensitive to cyclical demand shifts. With shares trading near $12.20—well below their 52-week high of $22.38—the earnings report will be critical in determining whether the selloff stabilizes or accelerates. A strong report could reverse the RSI-driven pessimism, while a weak result risks extending the decline into the next trading week.